rights foundational crispr intellectual property emmanuelle charpentier crispr pioneers space not confined pharma science company dupont formed alliances lithuania vilnius university caribou biosciences specific interest plant breeding agricultural applications interest pharmaceutical industry crispr cas9 gene editing taken year says bill lundberg chief scientific officer crispr therapeutics considerable time spent discussions companies organizations interested working deals rapid investment start firms aim commercialize crispr technology related products pharma sources funding caribou founded crispr pioneer jennifer doudna raised $ 15 million crispr therapeutics set charpentier raised $ 89 million april 2014 plus $ 105 million deal vertex editas founded current crispr patent holder